Patents by Inventor Wen-Lin Kuo
Wen-Lin Kuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240194646Abstract: A semiconductor package includes a substrate, first bumps, a first chip, metal pillars, second bumps and a second chip. The substrate includes first and second conductive pads which are located on a top surface of the substrate. Both ends of the first bumps are connected to the first conductive pads and the first chip, respectively. Both ends of the metal pillars are connected to the second conductive pads and one end of the second bumps, respectively. A cross-sectional area of each of the metal pillars is larger than that of each of the second bumps. The second chip is connected to the other end of the second bumps and located above the first chip.Type: ApplicationFiled: September 29, 2023Publication date: June 13, 2024Inventors: Chin-Tang Hsieh, Lung-Hua Ho, Chih-Ming Kuo, Chen-Yu Wang, Chih-Hao Chiang, Pai-Sheng Cheng, Kung-An Lin, Chun-Ting Kuo, Yu-Hui Hu, Wen-Cheng Hsu
-
Patent number: 9506926Abstract: Herein is described the use of a collection of 50 breast cancer cell lines to match responses to 77 conventional and experimental therapeutic agents with transcriptional, proteomic and genomic subtypes found in primary tumors. Almost all compounds produced strong differential responses across the cell lines produced responses that were associated with transcriptional and proteomic subtypes and produced responses that were associated with recurrent genome copy number abnormalities. These associations can now be incorporated into clinical trials that test subtype markers and clinical responses simultaneously.Type: GrantFiled: February 21, 2012Date of Patent: November 29, 2016Assignee: The Regents of the University of CaliforniaInventors: Paul T. Spellman, Joe W. Gray, Anguraj Sadanandam, Laura M. Heiser, William J. Gibb, Wen-lin Kuo, Nicholas J. Wang
-
Publication number: 20150080410Abstract: Developed here is a mitotic network comprising a signature of up to 54 genes, and including also sub-sets of genes within the signature, which can identify members by requiring higher correlation values for a signature gene. The present mitotic network provides for methods for prognosis and diagnosis of various cancers. The mitotic network is conserved across cancers exhibiting aberrant mitotic activity and several genes in the network act as therapeutic targets. Development of other inhibitors of mitosis can apply expression values of the genes in the mitotic network from patient tissue to select patients during clinical validation of the new drugs.Type: ApplicationFiled: May 19, 2014Publication date: March 19, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Zhi Hu, Jian-hua Mao, Wen-Lin Kuo, Ge Huang, Joe W. Gray
-
Patent number: 8404829Abstract: Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.Type: GrantFiled: January 19, 2006Date of Patent: March 26, 2013Assignees: The Regents of the University of California, The Board of Regents, University of Texas SystemInventors: Joe W. Gray, Yinghui Guan, Wen-Lin Kuo, Jane Fridlyand, Gordon B. Mills
-
Publication number: 20120222139Abstract: Developed here is a mitotic network comprising a signature of up to 54 genes, and including also sub-sets of genes within the signature, which can identify members by requiring higher correlation values for a signature gene. The present mitotic network provides for methods for prognosis and diagnosis of various cancers. The mitotic network is conserved across cancers exhibiting aberrant mitotic activity and several genes in the network act as therapeutic targets. Development of other inhibitors of mitosis can apply expression values of the genes in the mitotic network from patient tissue to select patients during clinical validation of the new drugs.Type: ApplicationFiled: November 8, 2011Publication date: August 30, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Zhi Hu, Jian-hua Mao, Wen-Lin Kuo, Ge Huang, Joe W. Gray
-
Publication number: 20120214829Abstract: Herein is described the use of a collection of 50 breast cancer cell lines to match responses to 77 conventional and experimental therapeutic agents with transcriptional, proteomic and genomic subtypes found in primary tumors. Almost all compounds produced strong differential responses across the cell lines produced responses that were associated with transcriptional and proteomic subtypes and produced responses that were associated with recurrent genome copy number abnormalities. These associations can now be incorporated into clinical trials that test subtype markers and clinical responses simultaneously.Type: ApplicationFiled: February 21, 2012Publication date: August 23, 2012Applicant: The Regents of the University of CaliforniaInventors: Paul T. Spellman, Joe W. Gray, Anguraj Sadanandam, Laura M. Heiser, William J. Gibb, Wen-Lin Kuo, Nicholas J. Wang
-
Patent number: 8198254Abstract: Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and miRNA) and shRNA adapted to inhibit ANXA9 expression, when formulated in a therapeutic composition, and delivered to cells of the tumor, function to treat the epithelial cancer.Type: GrantFiled: March 26, 2009Date of Patent: June 12, 2012Assignee: The Regents of the University of CaliforniaInventors: Zhi Hu, Wen-Lin Kuo, Richard M. Neve, Joe W. Gray
-
Publication number: 20110183336Abstract: Methods of-identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype and compositions for treating identified basal or luminal cancers.Type: ApplicationFiled: April 26, 2010Publication date: July 28, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: JOE W. GRAY, DEBOPRIYA DAS, WEN-LIN KUO, NICHOLAS J. WANG, RICHARD M. NEVE, PAUL T. SPELLMAN, JANE FRIDLYAND, KOEI CHIN, ZHI HU
-
Publication number: 20090318533Abstract: Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and miRNA) and shRNA adapted to inhibit ANXA9 expression, when formulated in a therapeutic composition, and delivered to cells of the tumor, function to treat the epithelial cancer.Type: ApplicationFiled: March 26, 2009Publication date: December 24, 2009Applicant: The Regents of the University of CaliforniaInventors: Zhi Hu, Wen-Lin Kuo, Richard M. Neve, Joe W. Gray
-
Publication number: 20090177450Abstract: Embodiments relate to genomic technologies using adaptive spline analysis that predict responses of cancer cells. For example, responses of cancer cells to specific medications and/or treatments may be predicted based on adaptive linear spline analyses.Type: ApplicationFiled: December 11, 2008Publication date: July 9, 2009Applicant: Lawrence Berkeley National LaboratoryInventors: Joe W. Gray, Debopriya Das, Nicholas Wang, Wen-Lin Kuo, Paul Spellman
-
Publication number: 20080312096Abstract: Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.Type: ApplicationFiled: January 19, 2006Publication date: December 18, 2008Applicant: The Regents of the University of CaliforniaInventors: Joe W. Gray, Yinghui Guan, Wen-Lin Kuo, Jane Fridlyand, Gordon B. Mills
-
Publication number: 20030077582Abstract: This invention pertains to the discovery that an amplification of some genes or an increase in that gene activity and a deletion of some genes or a decrease in that gene activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of the genes of the present invention within the biological sample; and (iii) comparing the level of one or more of said genes with a level of one or more of said genes in a control sample taken from a normal, cancer-free tissue.Type: ApplicationFiled: March 27, 2001Publication date: April 24, 2003Inventors: Wen-Lin Kuo, Daniel Polikoff, Daniel Pinkel, Donna Albertson, Andy Berchuck, Joe W. Gray
-
Publication number: 20020142305Abstract: This invention pertains to the discovery that an amplification of some genes or an increase in that gene activity and a deletion of some genes or a decrease in that gene activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., ovarian cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of the genes of the present invention within the biological sample; and (iii) comparing the level of one or more of said genes with a level of one or more of said genes in a control sample taken from a normal, cancer-free tissue.Type: ApplicationFiled: March 27, 2001Publication date: October 3, 2002Inventors: Koei Chin, Wen-Lin Kuo, Daniel Pinkel, Donna Albertson, Colin Collins, Joe W. Gray